학술논문

REV-ERB is essential in cardiac fibroblasts homeostasis
Document Type
article
Source
Frontiers in Pharmacology, Vol 13 (2022)
Subject
REV-ERB
fibroblast activation
SR9009
cardiac fibroblasts
TGFβ
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
1663-9812
Abstract
REV-ERB agonists have shown antifibrotic effects in the heart and other organs. The function of REV-ERB in the cardiac fibroblasts remains unstudied. Here, we characterize the functional difference of REV-ERB in mouse embryonic fibroblasts and cardiac fibroblasts using genetic deletion of REV-ERBα and ß in vitro. We show that REV-ERB α/β double deleted cardiac fibroblasts have reduced viability and proliferation, but increased migration and myofibroblasts activation. Thus, REV-ERB α/β has essential cell-autonomous role in cardiac fibroblasts in maintaining them in a healthy, quiescent state. We also show that existing REV-ERB agonist SR9009 strongly suppresses cardiac fibroblasts activation but in a REV-ERB-independent manner highlighting the need to develop novel REV-ERB agonists for treating cardiac fibrosis.